PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans
- 14 April 2005
- journal article
- clinical trial
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 17 (4) , 377-380
- https://doi.org/10.1038/sj.ijir.3901325
Abstract
Bone marrow-derived endothelial progenitor cells (EPCs) originate from haematopoietic stem cells in bone marrow and migrate into the peripheral circulation to promote endothelial repair and neovascularization. The number of circulating progenitor cells is reduced in patients with cardiovascular risk factor. The aim of our study was to determine the number of these cells in healthy patients and to evaluate the effect of Vardenfil, a phosphodiesterases-5 (PDE-5) inhibitor, in the number of circulating EPCs. In our study, we found a significant increase in the number of these cells after the drug administration.This publication has 8 references indexed in Scilit:
- Circulating endothelial progenitor cells in subjects with erectile dysfunctionInternational Journal Of Impotence Research, 2005
- The role of NOS3 in stem cell mobilizationTrends in Molecular Medicine, 2004
- Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis?Journal of Molecular Medicine, 2004
- Androgens Regulate Phosphodiesterase Type 5 Expression and Functional Activity in Corpora CavernosaEndocrinology, 2004
- Cardioprotection with phosphodiesterase-5 inhibition—a novel preconditioning strategyJournal of Molecular and Cellular Cardiology, 2004
- Age-dependent depression in circulating endothelial progenitor cells inpatients undergoing coronary artery bypass graftingJournal of the American College of Cardiology, 2003
- Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cellsNature Medicine, 2003
- Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-Week repeated oral administration in ratsBiopharmaceutics & Drug Disposition, 2003